User:Alisha, Deepa, Pamiz/Sandbox 1: Difference between revisions
Deepa Patel (talk | contribs) |
Deepa Patel (talk | contribs) |
||
| Line 36: | Line 36: | ||
Resistance to treatment with PPIs, including Esomeprazole, has been speculated among Barrett’s Esophagus (BE) patients who did not indicate any symptomatic improvement after being placed on a standard PPI drug dose.17 No contributory mutations causing PPI resistance have been found.17 It is speculated that the high acid exposure in BE patients may be due to “reflux diathesis” rather than resistance to gastric acid secretion.18 Other possible reasons for PPI failure include Helicobacter pylori infection, rapid metabolism, and bioavailability; reasons of clinical significance include delayed gastric emptying and visceral hypersensitivity17 . More studies need to be conducted to understand the mechanisms underlying the development of resistance to PPIs.17 | Resistance to treatment with PPIs, including Esomeprazole, has been speculated among Barrett’s Esophagus (BE) patients who did not indicate any symptomatic improvement after being placed on a standard PPI drug dose.17 No contributory mutations causing PPI resistance have been found.17 It is speculated that the high acid exposure in BE patients may be due to “reflux diathesis” rather than resistance to gastric acid secretion.18 Other possible reasons for PPI failure include Helicobacter pylori infection, rapid metabolism, and bioavailability; reasons of clinical significance include delayed gastric emptying and visceral hypersensitivity17 . More studies need to be conducted to understand the mechanisms underlying the development of resistance to PPIs.17 | ||
== References == | == References ==<references /> | ||
<references /> | |||